Nephrotoxicity is a major side effect of cisplatin, a widely used cancer therapy drug.
However, the mechanism of cisplatin nephrotoxicity remains unclear and no effective
kidney protective strategies are available. Here, we report the induction of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase
3 (PFKFB3) in both in vitro cell culture and in vivo mouse models of cisplatin nephrotoxicity.
Notably, PFKFB3 was mainly induced in the nucleus of kidney tubular cells, suggesting
a novel function other than its canonical role in glycolysis. Both pharmacological
inhibition and genetic silencing of PFKFB3 led to the suppression of cisplatin-induced
apoptosis in cultured renal proximal tubular cells (RPTCs). Moreover, cisplatin-induced
kidney injury or nephrotoxicity was ameliorated in renal proximal tubule-specific
PFKFB3 knockout mice. Mechanistically, we demonstrated the interaction of PFKFB3 with
cyclin-dependent kinase 4 (CDK4) during cisplatin treatment, resulting in CDK4 activation
and consequent phosphorylation and inactivation of retinoblastoma tumor suppressor
(Rb). Inhibition of CDK4 reduced cisplatin-induced apoptosis in RPTCs and kidney injury
in mice. Collectively, this study unveils a novel pathological role of PFKFB3 in cisplatin
nephrotoxicity through the activation of the CDK4/Rb pathway, suggesting a new kidney
protective strategy for cancer patients by blocking PFKFB3.
Abbreviations:
AKI (acute kidney injury), BUN (blood urea nitrogen), CKD (chronic kidney disease), CDKs (cyclin-dependent kinases), CDK4 (cyclin-dependent kinase 4), F2,6P2 (fructose-2,6-bisphosphate), Kim-1 (kidney injury molecule-1), OXPHOS (oxidative phosphorylation), PFK-1 (6-phosphofructo-1-kinase), PFK15 (1-(4pyridinyl)-3-(2-quinolinyl)-2-propen-1-one), PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3), p-Rb (phosphorylated Rb), Rb (retinoblastoma tumor suppressor), RPTCs (rat renal proximal tubular cells), SCr (serum creatinine), TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Translational ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cisplatin nephrotoxicity: mechanisms and renoprotective strategies.Kidney Int. 2008; 73: 994-1007
- Recent advances in models, mechanisms, biomarkers, and interventions in cisplatin-induced acute kidney injury.Int J Mol Sci. 2019; 20: 3011
- Potential therapeutic targets for cisplatin-induced kidney injury: lessons from other models of AKI and fibrosis.J Am Soc Nephrol. 2021; 32: 1559-1567
- Mitochondrial quality control in kidney injury and repair.Nat Rev Nephrol. 2021; 17: 299-318
- Cisplatin-induced kidney injury: delivering the goods.J Am Soc Nephrol. 2022; 33: 255-256
- Mechanisms of cisplatin nephrotoxicity.Toxins. 2010; 2: 2490-2518
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism, Cancer Metab, 2, 2014, 2.https://cancerandmetabolism.biomedcentral.com/articles/10.1186/2049-3002-2-2 Accessed January 23, 2014.
- Canonical and non-canonical roles of PFKFB3 in brain tumors.Cells. 2021; 10: 2913
- IGFBP5 promotes diabetic kidney disease progression by enhancing PFKFB3-mediated endothelial glycolysis.Cell Death Dis. 2022; 13: 340
- Characterization of a human placental fructose-6-phosphate, 2-kinase/fructose-2,6-bisphosphatase.J Biochem. 1997; 122: 122-128
- PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT.Cell Death Dis. 2018; 9: 428
- Non-canonical roles of PFKFB3 in regulation of cell cycle through binding to CDK4.Oncogene. 2018; 37: 1685-1698
- Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases.J Biol Chem. 2009; 284: 24223-24232
- IL-22-mediated renal metabolic reprogramming via PFKFB3 to treat kidney injury.Clin Transl Med. 2021; 11: e324
- Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms.Biochem Pharmacol. 2020; 177113939
- Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions.Proc Natl Acad Sci U S A. 2015; 112: 5231-5236
- CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury.Am J Physiol Renal Physiol. 2014; 306: F379-F388
- Immortalization and characterization of proximal tubule cells derived from kidneys of spontaneously hypertensive and normotensive rats.Kidney Int. 1996; 50: 125-134
- Endothelial PFKFB3 plays a critical role in angiogenesis.Arterioscler Thromb Vasc Biol. 2014; 34: 1231-1239
- Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor.Cancer Res. 2006; 66: 2576-2583
- PFKFB3-mediated endothelial glycolysis promotes pulmonary hypertension.Proc Natl Acad Sci U S A. 2019; 116: 13394-13403
- Inhibition of PKCdelta reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer.J Clin Invest. 2011; 121: 2709-2722
- Activation and involvement of p53 in cisplatin-induced nephrotoxicity.Am J Physiol Renal Physiol. 2007; 293: F1282-F1291
- MicroRNA-668 represses MTP18 to preserve mitochondrial dynamics in ischemic acute kidney injury.J Clin Invest. 2018; 128: 5448-5464
- p53 in proximal tubules mediates chronic kidney problems after cisplatin treatment.Cells. 2022; 11
- Tubular cells produce FGF2 via autophagy after acute kidney injury leading to fibroblast activation and renal fibrosis.Autophagy. 2022; : 1-22https://doi.org/10.1080/15548627.2022.2072054
- Canagliflozin reduces cisplatin uptake and activates Akt to protect against cisplatin-induced nephrotoxicity.Am J Physiol Renal Physiol. 2020; 318: F1041-F1F52
- Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury.Kidney Int. 2002; 62: 237-244
- Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease.Kidney Int. 2019; 95: 797-814
- Cyclin D-Cdk4,6 drives cell-cycle progression via the retinoblastoma protein's C-terminal helix.Mol Cell. 2019; 74 (e4): 758-770
- Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice.Mol Cell Biol. 1999; 19: 2251-2264
- Metabolic reprogramming by the S-nitroso-CoA reductase system protects against kidney injury.Nature. 2019; 565: 96-100
- Mitochondrial pathology and glycolytic shift during proximal tubule atrophy after ischemic AKI.J Am Soc Nephrol. 2016; 27: 3356-3367
- Glucose metabolism in acute kidney injury and kidney repair.Front Med (Lausanne). 2021; 8744122
- Decreased renal gluconeogenesis is a hallmark of chronic kidney disease.J Am Soc Nephrol. 2022; 33: 810-827
- Antibiotic-induced microbiome depletion alters renal glucose metabolism and exacerbates renal injury after ischemia-reperfusion injury in mice.Am J Physiol Renal Physiol. 2021; 321: F455-FF65
- Immunometabolic rewiring of tubular epithelial cells in kidney disease.Nat Rev Nephrol. 2022; 18: 588-603
- Role of PFKFB3 and PFKFB4 in cancer: genetic basis, impact on disease development/progression, and potential as therapeutic targets.Cancers (Basel). 2021; 13: 909
- Cyclin-dependent kinase inhibitor p18INK4c is involved in protective roles of heme oxygenase-1 in cisplatin-induced acute kidney injury.Int J Mol Med. 2014; 34: 911-917
- Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2.J Am Soc Nephrol. 2006; 17: 2434-2442
- Positive effect of the induction of p21WAF1/CIP1 on the course of ischemic acute renal failure.Kidney Int. 2001; 60: 2164-2172
- MicroRNA-687 induced by hypoxia-inducible factor-1 targets Phosphatase and Tensin homolog in renal ischemia-reperfusion injury.J Am Soc Nephrol. 2015; 26: 1588-1596
- Involvement of the CDK2-E2F1 pathway in cisplatin cytotoxicity in vitro and in vivo.Am J Physiol Renal Physiol. 2007; 293: F52-F59
- Cdk2-dependent phosphorylation of p21 regulates the role of Cdk2 in cisplatin cytotoxicity.Am J Physiol Renal Physiol. 2011; 300: F1171-F1179
- Integrating Old and New Paradigms of G1/S Control.Mol Cell. 2020; 80: 183-192
- Targeting CDK4 and CDK6 in cancer.Nat Rev Cancer. 2022; 22: 356-372
- Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment.Clin Cancer Res. 2015; 21: 2905-2910
- Drosophila cyclin D/Cdk4 regulates mitochondrial biogenesis and aging and sensitizes animals to hypoxic stress.Cell Cycle. 2012; 11: 554-568
- 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27.Cell Death Dis. 2014; 5: e1337
- The potential utility of PFKFB3as a therapeutic target.Expert Opin Ther Targets. 2018; 22: 659-674
- Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.J Exp Clin Cancer Res. 2017; 36: 7
- Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.Mol Cancer Ther. 2013; 12: 1461-1470
- PFKFB3 works on the FAK-STAT3-SOX2 axis to regulate the stemness in MPM.Br J Cancer. 2022; 127: 1352-1364
- PFKFB3 Inhibition sensitizes DNA crosslinking chemotherapies by suppressing Fanconi anemia repair.Cancers (Basel). 2021; 13: 3604
- Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis.Nat Commun. 2018; 9: 508
- Mutation of regulatory phosphorylation sites in PFKFB2 worsens renal fibrosis.Sci Rep. 2020; 10: 14531
- Macrophage metabolic reprogramming presents a therapeutic target in lupus nephritis.Proc Natl Acad Sci U S A. 2020; 117: 15160-15171
- Activation of cyclin D1-Cdk4 and Cdk4-directed phosphorylation of RB protein in diabetic mesangial hypertrophy.Diabetes. 2002; 51: 3290-3299
- Overall survival with Ribociclib plus Letrozole in advanced breast cancer.N Engl J Med. 2022; 386: 942-950
- Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.NPJ Breast Cancer. 2021; 7: 103
- Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.Nat Commun. 2021; 12: 5112
- Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.Lung Cancer. 2022; 166: 170-177
- Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.Nat Rev Urol. 2022; 19: 305-320
- A phase Ib/II study of the CDK4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer.Clin Cancer Res. 2022; 28: 1531-1539
Article info
Publication history
Published online: October 12, 2022
Accepted:
October 6,
2022
Received in revised form:
September 30,
2022
Received:
July 28,
2022
Identification
Copyright
Published by Elsevier Inc.
